|
1
|
Lei H, Fu J, Gu W, Qiao H, Guo H, Chen Z,
Wang SM and Chen T: Breast cancer: Molecular pathogenesis, targeted
therapy, screening, and prevention. MedComm (2020). 7:e705602026.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cancer Genome Atlas Network, .
Comprehensive molecular portraits of human breast tumours. Nature.
490:61–70. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dent R, Trudeau M, Pritchard KI, Hanna WM,
Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P and Narod SA:
Triple-negative breast cancer: Clinical features and patterns of
recurrence. Clin Cancer Res. 13:4429–4434. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lehmann BD, Bauer JA, Chen X, Sanders ME,
Chakravarthy AB, Shyr Y and Pietenpol JA: Identification of human
triple-negative breast cancer subtypes and preclinical models for
selection of targeted therapies. J Clin Invest. 121:2750–2767.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Palma M: Advancing breast cancer
treatment: The role of immunotherapy and cancer vaccines in
overcoming therapeutic challenges. Vaccines (Basel). 13:3442025.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lyons TG, Dickler MN and Comen EE:
Checkpoint inhibitors in the treatment of breast cancer. Curr Oncol
Rep. 20:512018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ye J, Wu S, Quan Q, Ye F, Zhang J, Song C,
Fan Y, Cao H, Tang H and Zhao J: Fibroblast growth factor receptor
4 promotes triple-negative breast cancer progression via regulating
fatty acid metabolism through the AKT/RYR2 signaling. Cancer Med.
13:e704392024. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Xu A, Li X, Cai Q, Yang C, Yang M, Gao H,
Cheng M, Chen X, Ji F, Tang H and Wang K: CircXPO6 promotes breast
cancer progression through competitively inhibiting the
ubiquitination degradation of c-Myc. Mol Cell Biochem.
480:1731–1745. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Emens LA: Breast cancer immunotherapy:
Facts and hopes. Clin Cancer Res. 24:511–520. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Loi S: Tumor-infiltrating lymphocytes,
breast cancer subtypes and therapeutic efficacy. Oncoimmunology.
2:e247202013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Adams S, Gray RJ, Demaria S, Goldstein L,
Perez EA, Shulman LN, Martino S, Wang M, Jones VE, Saphner TJ, et
al: Prognostic value of tumor-infiltrating lymphocytes in
triple-negative breast cancers from two phase III randomized
adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin
Oncol. 32:2959–2966. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dieci MV, Criscitiello C, Goubar A, Viale
G, Conte P, Guarneri V, Ficarra G, Mathieu MC, Delaloge S,
Curigliano G and Andre F: Prognostic value of tumor-infiltrating
lymphocytes on residual disease after primary chemotherapy for
triple-negative breast cancer: A retrospective multicenter study.
Ann Oncol. 25:611–618. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Adams S, Goldstein LJ, Sparano JA, Demaria
S and Badve SS: Tumor infiltrating lymphocytes (TILs) improve
prognosis in patients with triple negative breast cancer (TNBC).
Oncoimmunology. 4:e9859302015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mahmoud SMA, Paish EC, Powe DG, Macmillan
RD, Grainge MJ, Lee AH, Ellis IO and Green AR: Tumor-infiltrating
CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin
Oncol. 29:1949–1955. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Taube JM, Klein A, Brahmer JR, Xu H, Pan
X, Kim JH, Chen L, Pardoll DM, Topalian SL and Anders RA:
Association of PD-1, PD-1 ligands, and other features of the tumor
immune microenvironment with response to anti-PD-1 therapy. Clin
Cancer Res. 20:5064–5074. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tumeh PC, Harview CL, Yearley JH, Shintaku
IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu
V, et al: PD-1 blockade induces responses by inhibiting adaptive
immune resistance. Nature. 515:568–571. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu L, Bai X, Wang J, Tang XR, Wu DH, Du
SS, Du XJ, Zhang YW, Zhu HB, Fang Y, et al: Combination of TMB and
CNA stratifies prognostic and predictive responses to immunotherapy
across metastatic cancer. Clin Cancer Res. 25:7413–7423. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Brown SD, Warren RL, Gibb EA, Martin SD,
Spinelli JJ, Nelson BH and Holt RA: Neo-antigens predicted by tumor
genome meta-analysis correlate with increased patient survival.
Genome Res. 24:743–750. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kumari N, Dwarakanath BS, Das A and Bhatt
AN: Role of interleukin-6 in cancer progression and therapeutic
resistance. Tumour Biol. 37:11553–11572. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Warburg O: On the origin of cancer cells.
Science. 123:309–314. 1956. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chalmers ZR, Connelly CF, Fabrizio D, Gay
L, Ali SM, Ennis R, Schrock A, Campbell B, Shlien A, Chmielecki J,
et al: Analysis of 100,000 human cancer genomes reveals the
landscape of tumor mutational burden. Genome Med. 9:342017.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Samstein RM, Lee CH, Shoushtari AN,
Hellmann MD, Shen R, Janjigian YY, Barron DA, Zehir A, Jordan EJ,
Omuro A, et al: Tumor mutational load predicts survival after
immunotherapy across multiple cancer types. Nat Genet. 51:202–206.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rody A, Holtrich U, Pusztai L, Liedtke C,
Gaetje R, Ruckhaeberle E, Solbach C, Hanker L, Ahr A, Metzler D, et
al: T-cell metagene predicts a favorable prognosis in estrogen
receptor-negative and HER2-positive breast cancers. Breast Cancer
Res. 11:R152009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Iglesia MD, Parker JS, Hoadley KA, Serody
JS, Perou CM and Vincent BG: Genomic analysis of immune cell
infiltrates across 11 tumor types. J Natl Cancer Inst.
108:djw1442016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bedognetti D, Hendrickx W, Marincola FM
and Miller LD: Prognostic and predictive immune gene signatures in
breast cancer. Curr Opin Oncol. 27:433–444. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu Y, Hu Y, Xue J, Li J, Yi J, Bu J,
Zhang Z, Qiu P and Gu X: Advances in immunotherapy for
triple-negative breast cancer. Mol Cancer. 22:1452023. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Villacampa G, Navarro V, Matikas A,
Ribeiro JM, Schettini F, Tolosa P, Martínez-Sáez O, Sánchez-Bayona
R, Ferrero-Cafiero JM, Salvador F, et al: Neoadjuvant immune
checkpoint inhibitors plus chemotherapy in early breast cancer: A
systematic review and meta-analysis. JAMA Oncol. 10:1331–1341.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Das R, Deb S and Suresh PK: TMB as a
predictive biomarker for ICI response in TNBC: Current evidence and
future directions for augmented anti-tumor responses. Clin Exp Med.
26:252025. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang X and Chen H: Prognosis prediction
through an integrated analysis of single-cell and bulk
RNA-sequencing data in triple-negative breast cancer. Front Genet.
13:9281752022. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Thomas A, Routh ED, Pullikuth A, Jin G, Su
J, Chou JW, Hoadley KA, Print C, Knowlton N, Black MA, et al: Tumor
mutational burden is a determinant of immune-mediated survival in
breast cancer. Oncoimmunology. 7:e14908542018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bhattacharya S, Andorf S, Gomes L, Dunn P,
Schaefer H, Pontius J, Berger P, Desborough V, Smith T, Campbell J,
et al: ImmPort: Disseminating data to the public for the future of
immunology. Immunol Res. 58:234–239. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jézéquel P, Loussouarn D,
Guérin-Charbonnel C, Campion L, Vanier A, Gouraud W, Lasla H,
Guette C, Valo I, Verrièle V and Campone M: Gene-expression
molecular subtyping of triple-negative breast cancer tumours:
Importance of immune response. Breast Cancer Res. 17:432015.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Robinson MD, McCarthy DJ and Smyth GK:
edgeR: A bioconductor package for differential expression analysis
of digital gene expression data. Bioinformatics. 26:139–140. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu J, Lichtenberg T, Hoadley KA, Poisson
LM, Lazar AJ, Cherniack AD, Kovatich AJ, Benz CC, Levine DA, Lee
AV, et al: An integrated TCGA pan-cancer clinical data resource to
drive high-quality survival outcome analytics. Cell.
173:400–416.e11. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li T, Fan J, Wang B, Traugh N, Chen Q, Liu
JS, Li B and Liu XS: TIMER: A web server for comprehensive analysis
of tumor-infiltrating immune cells. Cancer Res. 77:e108–e110. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Giuliano AE, Connolly JL, Edge SB,
Mittendorf EA, Rugo HS, Solin LJ, Weaver DL, Winchester DJ and
Hortobagyi GN: Breast cancer-major changes in the American joint
committee on cancer eighth edition cancer staging manual. CA Cancer
J Clin. 67:290–303. 2017.PubMed/NCBI
|
|
37
|
McCarty KS Jr, Szabo E, Flowers JL, Cox
EB, Leight GS, Miller L, Konrath J, Soper JT, Budwit DA, Creasman
WT, et al: Use of a monoclonal anti-estrogen receptor antibody in
the immunohistochemical evaluation of human tumors. Cancer Res. 46
(8 Suppl):4244s–4248s. 1986.PubMed/NCBI
|
|
38
|
Vikas P, Borcherding N and Zhang W: The
clinical promise of immunotherapy in triple-negative breast cancer.
Cancer Manag Res. 10:6823–6833. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Halama A, Takada K, Takamori S, Haratake
N, Akamine T, Kinoshita F, Ono Y, Wakasu S, Tanaka K, Oku Y, et al:
Clinical significance of preoperative inflammatory markers in
non-small cell lung cancer patients: A multicenter retrospective
study. PLoS One. 15:e02415802020. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Dent R, Cortés J, Pusztai L, McArthur H,
Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, et al:
Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab
for early-stage triple-negative breast cancer: Quality-of-life
results from the randomized KEYNOTE-522 study. J Natl Cancer Inst.
116:1654–1663. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Schmid P, Rugo HS, Adams S, Schneeweiss A,
Barrios CH, Iwata H, Diéras V, Henschel V, Molinero L, Chui SY, et
al: Atezolizumab plus nab-paclitaxel as first-line treatment for
unresectable, locally advanced or metastatic triple-negative breast
cancer (IMpassion130): Updated efficacy results from a randomised,
double-blind, placebo-controlled, phase 3 trial. Lancet Oncol.
21:44–59. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Sukumar J, Gast K, Quiroga D, Lustberg M
and Williams N: Triple-negative breast cancer: promising prognostic
biomarkers currently in development. Expert Rev Anticancer Ther.
21:135–148. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Dvir K, Giordano S and Leone JP:
Immunotherapy in breast cancer. Int J Mol Sci. 25:75172024.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ravelli A, Roviello G, Cretella D,
Cavazzoni A, Biondi A, Cappelletti MR, Zanotti L, Ferrero G, Ungari
M, Zanconati F, et al: Tumor-infiltrating lymphocytes and breast
cancer: Beyond the prognostic and predictive utility. Tumour Biol.
39:10104283176950232017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Dushyanthen S, Beavis PA, Savas P, Teo ZL,
Zhou C, Mansour M, Darcy PK and Loi S: Relevance of
tumor-infiltrating lymphocytes in breast cancer. BMC Med.
13:2022015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Rizvi NA, Hellmann MD, Snyder A, Kvistborg
P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, et al: Cancer
immunology. Mutational landscape determines sensitivity to PD-1
blockade in non-small cell lung cancer. Science. 348:124–128. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Naing A, Infante JR, Papadopoulos KP, Chan
IH, Shen C, Ratti NP, Rojo B, Autio KA, Wong DJ, Patel MR, et al:
PEGylated IL-10 (Pegilodecakin) induces systemic immune activation,
CD8+ T cell invigoration and polyclonal T cell expansion
in cancer patients. Cancer Cell. 34:775–791.e3. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Bense RD, Sotiriou C, Piccart-Gebhart MJ,
Haanen JBAG, van Vugt MATM, de Vries EGE, Schröder CP and Fehrmann
RSN: Relevance of tumor-infiltrating immune cell composition and
functionality for disease outcome in breast cancer. J Natl Cancer
Inst. 109:djw1922016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zou Y, Zou X, Zheng S, Tang H, Zhang L,
Liu P and Xie X: Efficacy and predictive factors of immune
checkpoint inhibitors in metastatic breast cancer: A systematic
review and meta-analysis. Ther Adv Med Oncol.
12:17588359209409282020. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Egelston CA, Avalos C, Tu TY, Rosario A,
Wang R, Solomon S, Srinivasan G, Nelson MS, Huang Y, Lim MH, et al:
Resident memory CD8+ T cells within cancer islands mediate survival
in breast cancer patients. JCI Insight. 4:e1300002019. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Gatti-Mays ME, Balko JM, Gameiro SR, Bear
HD, Prabhakaran S, Fukui J, Disis ML, Nanda R, Gulley JL, Kalinsky
K, et al: If we build it they will come: Targeting the immune
response to breast cancer. NPJ Breast Cancer. 5:372019. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Doedens AL, Stockmann C, Rubinstein MP,
Liao D, Zhang N, DeNardo DG, Coussens LM, Karin M, Goldrath AW and
Johnson RS: Macrophage expression of hypoxia-inducible factor-1
alpha suppresses T-cell function and promotes tumor progression.
Cancer Res. 70:7465–7475. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Ruffell B, Chang-Strachan D, Chan V,
Rosenbusch A, Ho CM, Pryer N, Daniel D, Hwang ES, Rugo HS and
Coussens LM: Macrophage IL-10 blocks CD8+ T cell-dependent
responses to chemotherapy by suppressing IL-12 expression in
intratumoral dendritic cells. Cancer Cell. 26:623–637. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Montes VN, Turner MS, Subramanian S, Ding
Y, Hayden-Ledbetter M, Slater S, Goodspeed L, Wang S, Omer M, Den
Hartigh LJ, et al: T cell activation inhibitors reduce CD8+ T cell
and pro-inflammatory macrophage accumulation in adipose tissue of
obese mice. PLoS One. 8:e677092013. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Xu Y, Romero R, Miller D, Kadam L, Mial
TN, Plazyo O, Garcia-Flores V, Hassan SS, Xu Z, Tarca AL, et al: An
M1-like macrophage polarization in decidual tissue during
spontaneous preterm labor that is attenuated by rosiglitazone
treatment. J Immunol. 196:2476–2491. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Mao Y, Keller ET, Garfield DH, Shen K and
Wang J: Stromal cells in tumor microenvironment and breast cancer.
Cancer Metastasis Rev. 32:303–315. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Qian BZ and Pollard JW: Macrophage
diversity enhances tumor progression and metastasis. Cell.
141:39–51. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Daou HN: Exercise as an anti-inflammatory
therapy for cancer cachexia: A focus on interleukin-6 regulation.
Am J Physiol Regul Integr Comp Physiol. 318:R296–R310. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Denkert C, Loibl S, Noske A, Roller M,
Müller BM, Komor M, Budczies J, Darb-Esfahani S, Kronenwett R,
Hanusch C, et al: Tumor-associated lymphocytes as an independent
predictor of response to neoadjuvant chemotherapy in breast cancer.
J Clin Oncol. 28:105–113. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Lee HJ, Lee JJ, Song IH, Park IA, Kang J,
Yu JH, Ahn JH and Gong G: Prognostic and predictive value of
NanoString-based immune-related gene signatures in a neoadjuvant
setting of triple-negative breast cancer: Relationship to
tumor-infiltrating lymphocytes. Breast Cancer Res Treat.
151:619–627. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Lv Y, Lv D, Lv X, Xing P, Zhang J and
Zhang Y: Immune cell infiltration-based characterization of
triple-negative breast cancer predicts prognosis and chemotherapy
response markers. Front Genet. 12:6164692021. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Lin Y, Cui C, Su M, Silbart LK, Liu H,
Zhao J, He L, Huang Y, Xu D, Wei X, et al: Identification of TAPBPL
as a novel negative regulator of T-cell function. EMBO Mol Med.
13:e134042021. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Yu Y, Li J, Zhu X, Tang X, Bao Y, Sun X,
Huang Y, Tian F, Liu X and Yang L: Humanized CD7 nanobody-based
immunotoxins exhibit promising anti-T-cell acute lymphoblastic
leukemia potential. Int J Nanomedicine. 12:1969–1983. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Tokunaga R, Zhang W, Naseem M, Puccini A,
Berger MD, Soni S, McSkane M, Baba H and Lenz HJ: CXCL9, CXCL10,
CXCL11/CXCR3 axis for immune activation-a target for novel cancer
therapy. Cancer Treat Rev. 63:40–47. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Yi J, Shuang Z, Zhong W, Wu H, Feng J,
Zouxu X, Huang X, Li S and Wang X: Identification of immune-related
risk characteristics and prognostic value of immunophenotyping in
TNBC. Front Genet. 12:7304422021. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Katsuta E, Yan L, Opyrchal M, Kalinski P
and Takabe K: Cytotoxic T-lymphocyte infiltration and chemokine
predict long-term patient survival independently of tumor
mutational burden in triple-negative breast cancer. Ther Adv Med
Oncol. 13:175883592110066802021. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Li F, Zhang R, Li S and Liu J: IDO1: An
important immunotherapy target in cancer treatment. Int
Immunopharmacol. 47:70–77. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Cheong JE and Sun L: Targeting the
IDO1/TDO2-KYN-AhR pathway for cancer immunotherapy-challenges and
opportunities. Trends Pharmacol Sci. 39:307–325. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Pérez-Pena J, Tibor Fekete J, Páez R,
Baliu-Piqué M, García-Saenz JÁ, García-Barberán V, Manzano A,
Pérez-Segura P, Esparis-Ogando A, Pandiella A, et al: A
Transcriptomic immunologic signature predicts favorable outcome in
neoadjuvant chemotherapy treated triple negative breast tumors.
Front Immunol. 10:28022019. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Castro F, Cardoso AP, Gonçalves RM, Serre
K and Oliveira MJ: Interferon-gamma at the crossroads of tumor
immune surveillance or evasion. Front Immunol. 9:8472018.
View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Burke JD and Young HA: IFN-γ: A cytokine
at the right time, is in the right place. Semin Immunol.
43:1012802019. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Yeong J, Lim JCT, Lee B, Li H, Ong CCH,
Thike AA, Yeap WH, Yang Y, Lim AYH, Tay TKY, et al: Prognostic
value of CD8 + PD-1+ immune infiltrates and PDCD1 gene expression
in triple negative breast cancer. J Immunother Cancer. 7:342019.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Chen J, Gao G, Wang H, Ye X, Zhou J and
Lin J: Expression and clinical significance of latent-transforming
growth factor beta-binding protein 2 in primary hepatocellular
carcinoma. Medicine (Baltimore). 98:e172162019. View Article : Google Scholar : PubMed/NCBI
|
